Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer

NCT ID: NCT02046538

Last Updated: 2017-01-25

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-28
• Study Completion Date: 2018-02-28

Brief Summary

The purpose of this study is to establish the safety of Zaltrap in patients who undergo pre-operative chemotherapy with Zaltrap. The investigators hypothesize that Zaltrap my impact colorectal cancer growth and metastasis.

Detailed Description

Eligible patients will receive 3 months of chemotherapy consisting of either FOLFOX or FOLFIRI (in the case of liver limited CRC) or FOLFOX (in the case of rectal cancer). The FOLFOX regimen consists of Oxaliplatin, Leucovorin, and 5-FU. The FOLFIRI regimen consists of Irinotecan, Leucovorin, and 5-FU. Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 week's from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.

Following resection, patients will be randomly assigned (1:1) to receive chemotherapy with or without zaltrap for 3 additional months. Patients assigned to Zaltrap may continue zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months. Patients will have research blood draws periodically both in the preoperative and postoperative period.

The investigators plan to demonstrate that pre-operative chemotherapy with Zaltrap is not associated with any safety signals that would preclude further drug development in this patient population. The investigators also plan to perform correlative studies to identify potential biomarkers for Zaltrap activity.

The investigators hypothesize that antiangiogenic therapy may specifically target the micrometastatis niche of patients with liver limited metastatic colorectal cancer to significantly increase the chance of cure for these patients.

Conditions

Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Postoperative Chemo WITH Zaltrap

Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.

Following resection, patients will receive chemotherapy with zaltrap for 3 additional months. Patients may continue zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months.

Group Type: EXPERIMENTAL

Leucovorin

Intervention Type: DRUG

400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)

Oxaliplatin

Intervention Type: DRUG

85 mg/m2 IV over two hours

5-FU

Intervention Type: DRUG

400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours

Irinotecan

Intervention Type: DRUG

180 mg/m2 IV over 90 minutes

Postoperative chemo WITHOUT zaltrap

Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.

Following resection, patients will receive chemotherapy (without zaltrap) for 3 additional months.

Group Type: ACTIVE_COMPARATOR

Leucovorin

Intervention Type: DRUG

400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)

Oxaliplatin

Intervention Type: DRUG

85 mg/m2 IV over two hours

5-FU

Intervention Type: DRUG

400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours

Irinotecan

Intervention Type: DRUG

180 mg/m2 IV over 90 minutes

Interventions

Leucovorin

400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)

Intervention Type: DRUG

Oxaliplatin

85 mg/m2 IV over two hours

Intervention Type: DRUG

5-FU

400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours

Intervention Type: DRUG

Irinotecan

180 mg/m2 IV over 90 minutes

Intervention Type: DRUG

Other Intervention Names

Wellcovorin; Eloxatin; Adrucil, fluorouracil; Camptosar

Eligibility Criteria

Inclusion Criteria

• Patients must have pathologically confirmed adenocarcinoma of the colon or rectum.
• In patients with liver-limited metastatic colorectal cancer, a curative approach is indicated following evaluation by hepatobiliary surgeon as part of multidisciplinary management. Select patients requiring two stage procedure are also eligible following evaluation by hepatobiliary surgeon as part of multidisciplinary management.
• In patients with rectal cancer, primary tumor that is clinically T3-4 or N + (evaluation by colorectal surgery is required as part of multidisciplinary approach).
• No prior chemotherapy for metastatic disease is allowed for patients with CRC-liver mets. (adjuvant FOLFOX is permitted)
• No prior chemotherapy for proximal rectal cancer is allowed
• ECOG Performance status ≤ 2.
• Age >18 years old.
• Patients must have adequate bone marrow, kidney, and liver function as assessed by laboratory parameters.

1. WBC ≥ 3,000/uL

2. Total Bilirubin ≤ 1.5 x upper limits of normal

3. AST (SGOT) ≤ 3 x upper limits of normal

4. ALT (SGPT) ≤ 3 x upper limits of normal

5. Hemoglobin ≥ 9.0 g/dl (without transfusion within 7 d)

6. ANC ≥ 1500 /ml

7. Platelets ≥100 K/ml (without transfusion)

8. Calculated CrCL > 50 ml/min

• Ability to understand and the willingness to sign a written informed consent document.
• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.

Exclusion Criteria

• Patients with untreated CNS metastases.
• Significant medical co-morbidity that would preclude safe administration of cytotoxic therapy, including but not limited to:

1. Cardiovascular disease

1. Unstable angina

2. Myocardial infarction/ CABG < 3 months prior to study initiation

3. Untreated coronary artery disease

4. NYHA class III or IV heart failure

2. Ongoing serious infection

1. Bacteremia or sepsis requiring intravenous antibiotics

2. HIV with AIDS defining illness

3. Inadequate oral nutritional intake: Requirement for daily intravenous fluids or total parenteral nutrition.

4. Neurological: Stroke ≤ 6 months

5. Psychiatric illness/social situations that would limit compliance with study requirement

• Patients may not receive another investigational agent.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Ziv-aflibercept.
• Pregnant (positive pregnancy test) and lactating women are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown.
• Major surgical procedure ≤ 4 weeks from starting therapy.
• Grade 3-4 hemorrhage, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or diverticulits ≤ 3 months from starting therapy.
• Patients with known DPD deficiency
• Patients with known Gilbert's syndrome
• Patients with ≥ 2g/24 hour urine protein. If urine protein on random UA is ≤ 300 mg/dl, a 24 hour urine protein is not required.
• Symptomatic peripheral sensory neuropathy grade ≥ 2.
• Other malignancy within the last 5 years from study entry, except for basal /squamous cell skin cancer, in situ cervical cancer, or non-metastatic prostate cancer.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: collaborator

Weill Medical College of Cornell University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Manish A. Shah, MD

Role: PRINCIPAL_INVESTIGATOR

Weill Medical College of Cornell University

Locations

Weill Cornell Medical College

New York, New York, United States

Countries

United States

Other Identifiers

2012-AFL-18

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

1309014302

Identifier Type: -

Identifier Source: org_study_id